Lundbeck-Takeda Drug Fights Depression Better at Higher Dose

H. Lundbeck A/S, Denmark’s second-largest drugmaker, said its experimental antidepressant Brintellix improved symptoms better in a higher dose in a late-stage U.S. study, as the medicine awaits regulatory approval.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.